Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 April 1994Website:
http://www.soligenix.comNext earnings report:
21 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:51:34 GMTDividend
Analysts recommendations
Institutional Ownership
SNGX Latest News
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET).
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares.
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024.
Annual Meeting to be held May 23, 2024 PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to participate in the upcoming Annual Meeting of Stockholders to be held virtually at 9:00AM ET on May 23, 2024.
Results of Phase 3 FLASH Study Confirm and Expand on Response Findings Published PRINCETON, N.J., May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on rare disease treatments, has announced the publication of compatibility study results for HyBryte™ in treating CTCL in the Journal of the European Academy of Dermatology & Venereology (JEADV) Clinical Practice.
Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company specializing in rare disease treatments, will be presenting at the following upcoming conferences.
Shares of Soligenix (NASDAQ:SNGX) jumped over 44% following the company's receipt of Orphan Drug Designation from US regulators for the active component in its MarVax vaccine, which targets the Marburg virus that leads to Marburg Virus Disease. This designation pertains to the prevention and treatment of MARV infection.
Soligenix (NASDAQ: SNGX) stock is surging today following the announcement of an orphan drug designation for the active ingredient in MarVax by the FDA's Office of Orphan Products Development.
Soligenix (NASDAQ:SNGX) shares added almost 35% before the opening bell on Tuesday after it revealed its novel vaccine provided 100% protection against two deadly infections in non-human primate models. The company said that its single-vial bivalent vaccine demonstrated simultaneous protection against Sudan ebolavirus and Marburg Marburgvirus, two conditions for which there are no approved vaccines or therapeutics, in the preclinical evaluation.
Soligenix (NASDAQ: SNGX ) stock is on the rise Thursday after the company got approval from the Food and Drug Administration for a Phase 2a clinical trial of SGX945. According to a press release from Soligenix, this clinical trial covers the safety and efficacy of SGX945 as a potential treatment for aphthous ulcers in Behçet's Disease.
What type of business is Soligenix?
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
What sector is Soligenix in?
Soligenix is in the Healthcare sector
What industry is Soligenix in?
Soligenix is in the Biotechnology industry
What country is Soligenix from?
Soligenix is headquartered in United States
When did Soligenix go public?
Soligenix initial public offering (IPO) was on 04 April 1994
What is Soligenix website?
https://www.soligenix.com
Is Soligenix in the S&P 500?
No, Soligenix is not included in the S&P 500 index
Is Soligenix in the NASDAQ 100?
No, Soligenix is not included in the NASDAQ 100 index
Is Soligenix in the Dow Jones?
No, Soligenix is not included in the Dow Jones index
When does Soligenix report earnings?
The next expected earnings date for Soligenix is 21 August 2024